Browsing Tag
Cabenuva
5 posts
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
GSK Q1 2025 earnings: Specialty medicines power growth as pipeline builds investor confidence
GSK's Q1 2025 earnings beat forecasts on strong Specialty Medicines growth and pipeline strength—read full results, investor sentiment, and stock outlook.
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients.…